Roots Analysis Identifies Top 5 Radiopharmaceutical Companies
Roots Analysis has identified five key players in the rapidly evolving radiopharmaceuticals market. These companies represent innovation and growth in the sector.
New York, USA – In September 2026, market research firm Roots Analysis released a report identifying the top five companies in the radiopharmaceutical sector. Radiopharmaceuticals combine the diagnostic and therapeutic potential of radioactive isotopes with molecules designed to target specific cancer cells, offering a more precise treatment approach than traditional therapies.
The market is being shaped by growing interest in "theranostics," a model that pairs imaging and therapy using related compounds. Prostate cancer and neuroendocrine tumors are emerging as key application areas. Advances in isotope supply chains, radiochemistry, and manufacturing capabilities are also supporting broader commercialization.
The Roots Analysis report, "Top 5 Radiopharmaceutical Companies," analyzes the current market landscape and future opportunities over the next 14 years. The identified leading companies include 3BP Pharmaceuticals, Curium, ITM Radiopharma, Jubilant Radiopharma, and Lantheus.
The report provides detailed insights into the operations and recent developments of these companies. For instance, 3BP Pharmaceuticals entered a collaboration in April 2026 with TetraKit to develop a novel cancer treatment labeled with astatine-211, a promising alpha-emitting radionuclide.